Our Buzz Stock of the Day — Antigenics, Inc. (Nasdaq: AGEN) — was the big winner of today’s bio-tech rally.

Earlier this week, Antigenics said an analysis of patient data showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46 percent lower risk of death when treated with the company’s Oncophage^® (vitespen) cancer therapy. Oncophage is currently approved only in Russia. The company has also filed for approval in the European Union.
Shares of Antigenics have risen almost 250% over the last 30 days.

“Demonstration of an overall survival benefit remains the gold standard, and these interim results show that Oncophage has a real promise of improving survival in patients with earlier-stage disease for whom current prognosis remains poor,” said Dr. Christopher Wood, who presented the survival results at the annual meeting of the American Society of Clinical Oncology. “Based on these results, Oncophage offers these patients a potential treatment that extends survival without significant toxicities.”